24/7 Market News Snapshot 04 September, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)

September 4, 2025

DENVER, Colo., 04 September, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc., a biopharmaceutical company at the forefront of developing therapies for rare diseases, is currently witnessing a notable surge in its stock performance, with pre-market shares rising by 14.29% to $3.520. This increase follows a closing price of $3.080 in the previous session, alongside a trading volume of 1.83 million, signaling heightened investor interest and market momentum. Traders are advised to monitor critical support levels near $3.00 and resistance points at $3.70, as any continuation of this bullish trend could lead to further gains. However, a decline below the $3.30 threshold may indicate a potential downturn.

In a significant development, the company has also announced a breakthrough in vaccine stability with its proprietary ThermoVax® technology. A recent manuscript highlights the long-term stability of ebolavirus vaccines, which have demonstrated efficacy at elevated temperatures of 40°C (104°F) over a two-year period. This achievement is a collaborative effort with Dr. Axel Lehrer of the John A. Burns School of Medicine and is set to be published in the journal Vaccine.

Dr. Lehrer remarked on the implications of these findings for vaccination strategies, particularly in endemic regions, emphasizing the benefits of a single-vial subunit vaccine capable of shipping without stringent cold chain requirements. Christopher J. Schaber, PhD, President and CEO of Soligenix, underscored the transformative potential of these thermostabilized vaccines in enhancing public health logistics and efficacy. These advancements reaffirm Soligenix’s commitment to addressing critical medical needs and advancing biopharmaceutical innovation on a global scale.

Related news for (SNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.